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Antibiotic resistance is an increasingly difficult problem in the clinic, where conventional 
antibiotics are failing, and new alternative solutions are in high demand. Infections caused by 
Gram-negative bacteria with multi drug resistance (MDR) mechanisms are increasing globally, 
and treatment options are limited. Plasmids encoding β-lactamases spread easily between 
bacteria, and the overuse of antibiotics select for MDR strains. β-lactamases are either serine-
β-lactamases that are inhibited by certain β-lactamase inhibitors, and metallo-β-lactamases 
(MBLs), which are more difficult to inhibit with drugs. The current approach to fight MDR 
pathogens has mainly focused on finding β-lactamase inhibitors to use in combination with 
conventional antibiotics in the clinic.  
The overall aim of this thesis was to study the role of the cellular micro-environment and the 
importance of the innate immune system for antibiotic resistant bacterial infections.  
In Paper I we hypothesized that human cells secreted factors that could impair β-lactamase 
function and thus restore antibiotic susceptibility in resistant bacterial isolates. We found that 
thiols produced by the cells acted as zinc chelators that inhibited the degradation of 
cephalosporin antibiotics in VIM-1 producing K. pneumoniae. Notably, free thiols in urine 
samples had the same effect, suggesting that the environment at the site of infection can be 
highly important for antibiotic susceptibility and possibly also for the effect of antibiotic 
treatment in a clinical situation 
In Paper II, we hypothesized that induction of innate effector molecules would reduce 
intracellular growth of MDR K. pneumoniae and exert synergistic effects with conventional 
antibiotics. We tested this by infecting human macrophages with MDR K. pneumoniae. 
Notably, induction of innate immunity in these cells resulted in improved intracellular killing 
of MDR K. pneumoniae. The inducers were combined with traditional antibiotics, which 
resulted in an additive killing effect. The data suggests that inducing innate immune effectors 
can be an effective alternative or addition to conventional treatments in infections caused by 
MDR K. pneumoniae. 
Finally, in Paper III, we tested the hypothesis that ESBL E. coli would be more susceptible to 
innate effectors compared to non-ESBL isolates. The ESBL producing isolates had lower 
survival in serum and whole blood than non-ESBL isolates, suggesting a biological cost for 
resistant isolates. In vivo studies with zebrafish embryos showed that the non-ESBL isolates 
killed the embryos more efficiently than ESBL isolates. The biological cost was not related to 
the ESBL plasmid per se as shown by experiments where the ESBL plasmid was transferred 
from a clinical isolate to a neutral background in non-resistant E. coli.  
Together, this thesis has highlighted the importance of considering the micro-environment at 
the site of infection, which may determine the effect of antibiotics. Next, I have shown that 
induction of innate immune effectors could be an alternative or additive treatment option for 
infections caused by MDR K. pneumoniae. Finally, I present data showing that ESBL E. coli 
are more susceptible to innate effectors than non-ESBL E. coli. 
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Bacterial strains may acquire resistance at a fast rate, and MDR strains have rapidly 
circumvented the effects of many available antibiotics. There is an undisputable need for a 
better understanding and improved treatment of infections caused by antibiotic resistant 
bacteria, which have become problematic in hospital settings, the community and environment 
in many parts of the world. The population most affected by antibiotic resistant bacterial 
infections are the elderly and immunocompromised, resulting in a higher risk for sepsis and 
death and making the hospital setting an important arena for the rise in resistant bacterial 
strains. This is not only affecting survival rates of patients, but is also associated with a high 
cost increase for the health care sector, where morbidity, mortality and lengths of hospital stays 
increase1. It is estimated that the number of annual deaths caused by antimicrobial resistance 
will reach 10 million in the year 2050. In comparison, the number of deaths caused by road 
traffic accidents, cancer and diabetes combined are expected to be around 11 million 
annually2,3,4.  
Hospital acquired infections come in fifth as the leading cause of death in the acute care, where 
the at-risk population is mainly infants, the elderly and immunocompromised patients. Within 
the hospital setting, bacteria can spread from health care workers to patients as well as between 
patients. Importantly, opportunistic bacteria can use plastic devices, such as catheters and 
ventilators as scaffolds for their growth and may thus cause disease. It is important to take 
preventive measures to inhibit the transmission between patients with proper hand hygiene, 
which has been shown to be effective. With the rise of antibiotic resistance, hospital-acquired 
infections are becoming increasingly difficult to handle5. The burden of disease varies for 
different bacteria, where extended spectrum cephalosporin resistant Gram-negative bacteria, 
together with carbapenem resistant Gram-negative bacteria constitute a special and emerging 
problem1. 
The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp) are of 
high interest because of their ability to become resistant to our available antibiotics. In recent 
years, the level of threat has shifted from the Gram-positive methicillin-resistant 
Staphylococcus aureus (MRSA) to Gram-negative β-lactamase producing strains. From that 
category the World Health Organization (WHO) published a list of bacteria that are considered 
a priority and in urgent need for new antibiotics; the Gram-negative E. coli, K. pneumoniae and 
P. aeruginosa are in priority 1. The field of antibiotic resistance has mostly focused on the 
bacterial pathogens and mechanisms of resistance within the bacteria6, while the contribution 
of host immunity has been overlooked and understudied. This thesis will focus on two highly 
relevant groups of antibiotic resistance mechanisms, the extended spectrum β-lactamases 
(ESBL) and carbapenemases and how bacteria that can acquire these resistance mechanisms 





1. INNATE IMMUNE DEFENSES 
For bacteria to establish infections, a first step is to circumvent the efficient and thorough innate 
immune system. The bacteria need to enter from the environment, through the mucosal and 
epithelial barrier and into the bloodstream to cause an infection, commonly through the 
digestive tract or the urinary tract. For the bacteria to enter through the epithelial barrier into 
the bloodstream, there is a need to overcome obstacles, such as antimicrobial peptides (AMPs), 
the mucosal barrier, tight junctions, phagocytes, and when it comes to the bloodstream the 
complement system is important to mediate bacterial killing7. 
1.1 THE MUCOSAL BARRIER SYSTEM 
The mucosal barrier that separates our internal organs from the external environment consists 
of different parts that include, from the outer layer inwards; a layer of commensal bacteria that 
form the microbiota, a mucus layer that gradually increases in thickness, and the epithelial cell 
layer. The commensal bacteria exist in symbiosis with the host and can be found in e.g. the 
gastrointestinal tract, the urinary tract, the lungs and the skin. They are essential for the host 
because of their direct competition with potential pathogens as well as their production of 
metabolites, such as butyrate and other short chain fatty acids, that can induce AMP- production 
in epithelial cells, as well as provide important nutrition for these cells. In addition, the 
microbiota can influence the function of immune cells in the submucosa, and reciprocally the 
immune cells can regulate the microbiota, keeping a controlled environment without 
inflammation. Underneath the microbiota, pathogens encounter a mucus layer consisting of a 
thick mucus (mucin proteins and lipids) produced by goblet cells in the epithelial layer. The 
epithelial layer itself is a network connected via tight junctional structures to prevent the 
invasion of microbes. If the pathogen succeeds to enter through the epithelial barrier, it will 
encounter an army of phagocytic cells that reside in the connective tissue (Figure 1)8. Both 
epithelial cells and immune cells express pattern recognition receptors (PRRs), such as the Toll-
like receptors (TLRs) and cytoplasmic NOD-like receptors (NLRs). These receptors recognize 
conserved microbe-associated molecular patterns (MAMPs), which upon binding cause 
structural changes to the receptor complex that initiates intracellular mechanisms, such as the 
NFκB pathways that are important for initiating inflammatory responses. Depending on the 
type of MAMP sensed by the receptor, different pro-inflammatory states can be regulated. If a 
bacteria reaches or breaches through the epithelial cell layer, the PRRs sense the different 
MAMPs, such as flagellin, peptidoglycan and lipopolysaccharide (LPS). Once cells are 
activated through their PRRs, they react by either communication through cytokines with other 





















Figure 1. The mucosal barrier. The mucosal barrier is regulated by cross talk between the microbiota, epithelial 
cells and immune cells. A gradient of mucus prevents the commensal bacteria to come in contact with the cells, 
keeping a homeostasis without inflammation. Picture adapted from Wu et al10. 
 
1.2 ANTIMICROBIAL PEPTIDES 
AMPs are recognized for their potent bactericidal activity and play an important role in the first 
line of defense against invading bacteria. They are expressed in both epithelial cells and 
leukocytes, such as macrophages and neutrophils. AMPs are amphipathic with a net positive 
charge as well as a hydrophobic side. Their antimicrobial mechanism of action is thought to 
involve an initial electrostatic interaction with lipids in the bacterial outer membrane or cell 
wall and a subsequent secondary hydrophobic contact that disrupts the membrane, leading to 
bacterial lysis4. AMPs can also have additional functions not directly related to their 
antimicrobial activity, such as chemotaxis, anti-tumor activity, stimulation of cell proliferation, 
LPS neutralization and degranulation of mast cells11,12. 
AMPs can be subdivided in different families, with the major families in mammals being the 
cathelicidins and the defensins. The defensins are further characterized into two families, α and 
β-defensins, that are similar in secondary structure (small and cysteine rich), but lack homology 
in amino acid sequence11. LL-37 is the only human cathelicidin and its expression can be 
induced by different stimuli and molecules. For example, vitamin D3 has a major role in the 
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regulation of  LL-37 expression13. Additional known inducers of LL-37 are butyrate (abundant 
in the gut)14 and  its synthetic analogue phenylbutyric acid (PBA)15 as well as Entinostat16, that 
function as histone deacetylase inhibitors  (HDAC inhibitors). Importantly, while the 
identification of novel AMP inducers is interesting from a biological point of view, it has also 
given rise to the development of host directed therapy (HDT) to fight infections, an innovative 
potential therapeutic approach to counter bacterial infections through stimulation of the host 
immune system by exogenously applied small-molecular compounds13. 
 
1.3 ANTIMICROBIAL PROTEINS 
In addition to AMPs, antimicrobial proteins (defined as mature and active proteins larger than 
100 amino acids) are present in humans, which can exert direct or indirect killing of bacteria19. 
For instance, lysozyme is an enzyme abundantly found in tears, saliva and mucus. It catalyzes 
the hydrolysis of the peptidoglycan in the bacterial cell wall, resulting in lysis of the bacteria. 
Gram-positive bacteria are highly susceptible to the activity of lysozyme20, whereas Gram-
negative bacteria are protected by LPS of the outer membrane. Other antimicrobial proteins are 
for example lactoferrin, calprotectin and lipocalin-2 (LCN2). LCN2 is a 25 kDa secretory 
glycoprotein that was originally purified from neutrophils21, but is also expressed by epithelial 
cells and is upregulated upon stress, such as gastrointestinal damage, bacterial infection or 
inflammation22. The antimicrobial activity of LCN2 comes from its ability to bind and 
neutralize iron bound siderophores, which allows it to compete for available iron and prevent 
bacterial iron acquisition that is essential for the bacterial growth23. Siderophores are produced 
by some bacterial strains, including Klebsiella pneumoniae, and are secreted to acquire iron 
from the environment24.  
 
1.4 CELLS OF THE INNATE IMMUNITY  
One important component of innate immunity are phagocytes that directly attack or engulf 
invading bacteria. They are found in tissues or circulating in the bloodstream, where they search 
for foreign invaders. Professional phagocytes include macrophages, neutrophilic granulocytes 
and dendritic cells. Macrophages can be either tissue resident or differentiate from blood 
derived monocytes upon entering inflamed tissues and phagocytose microbes that have 
penetrated the mucosal barriers. Upon activation, these macrophages also promote secretion of 
cytokines and chemokines that recruit more immune cells to the site of infections. Neutrophils 
contain granules filled with various antimicrobial factors, including AMPs. Once a bacterium 
is phagocytosed, these granules fuse with the bacteria-containing phagosome, promoting direct 
killing of the pathogen25. Another part of the antimicrobial arsenal of phagocytes is reactive 
oxygen species (ROS). The release of ROS is largely depending on external factors, such as 
stress and the presence of microbes, and can either be considered beneficial as an immune 
response, or harmful in the case of excessive stress26,27. The general ROS production and 
release is highly regulated, and mostly generated in the mitochondria. The cells maintain ROS 
 
 5 
at low levels and exhibit a steady-state to reach a balance of generation and elimination of the 
free radicals28. In phagocytes, ROS are mainly produced by a multiprotein electron transferase 
NADPH oxidase (NOX2) complex. The produced ROS can oxidize proteins, DNA and 




















Figure 2. TLR activation results in an innate immune respnse. A bacterial component is recognized by a 
TLR-receptor on the cell surface, resulting in regulation of genes that promote an innate immune response. 
Picture adapted from Stocks, et al (2018)30. 
 
Finally, the dendritic cells serve a special function among phagocytes and provide a link 
between the innate immune system and the adaptive immune system through antigen 
presenting abilities. They can activate T cells by presenting phagocytosed antigens and 







Although all of the above mentioned cell types are important for the innate immune system, 
I have mainly worked with macrophages as a model system in this thesis. Monocyte derived 
macrophages (MDMs) have previously been catagorized into two types; M1 and M2 
depending on the polarization and inflammatory state of the cells. The fundamentals of the 
characterization is based on the observation that macrophages either kill pathogens (M1 
type), while other macrophages contribute to tissue repair (M2 type)32, in other words pro-
inflammatory (M1) or anti-inflammatory (M2) responses. Although it is convenient to 
group the macrophages into two distinct groups, this characterization may represent a 
simplistic view33. In vitro macrophages can be induced by certain compounds that 
differentiate them into M1 (GM-CSF, INFᵧ and LPS) or M2 (M-CSF and IL-4) 
macrophages. However, the situation in vivo represent a much more complex system 34. 
The M1/M2 paradigm can be considered as a spectrum, where certain stimuli also can cause 
the cells to differentiate outside of the spectrum. Since macrophages are considered specific 
to the organ they reside in and have the ability to alter their location-based differentiation, 
it can be concluded that the double-ended M1-M2 spectrum can be useful for simple 
clarification of the inflammatory responses, but not enough to characterize the cell type33,35. 
Macrophages can detect pathogens through various pattern recognition receptors that sense 
common and conserved components of pathogens, receptors such as the toll-like-receptors 
(TLR). TLRs can bind to microbial components, where the most extensively studied 
antigen-receptor binding is the lipopolysaccharide (LPS) binding to TLR-4. Upon binding, 
a signaling cascade initiates an innate immune response leading to cell activation through 
the NFκB pathway, resulting in a pro-inflammatory response36. 
When a macrophage is activated, different forms of defense mechanisms can be initiated 
to eliminate pathogens in the extra- or intracellular compartments. Cytokines and 
chemokines are secreted to activate and recruit more immune cells, as well as AMPs and 
ROS for direct killing of the pathogen. When the pathogen is phagocytosed, intracellular 
elimination mechanisms occur, where autophagy is an important contributing factor in the 
pathogen elimination. The pathogen is transfered by several regulated steps to the 
autophagosome and fuses with the lysosome, where autophagy can promote the addition 
of antimicrobial peptides and ROS to the lysosome to enhance the killing. This form of 
autophagy is regulated by genes downstream the NFκB pathway, such as the ATG genes 
(ATG-14, ATG-5, Beclin-1). Autophagy is particularly important for the control of 
intracellular bacterial infections. However, certain virulent bacteria, including 







1.5 ANTIMICROBIAL FACTORS IN THE BLOOD 
The blood has many different antimicrobial components. A potent antimicrobial response is 
the complement mediated killing of bacteria in serum. When bacteria enter the bloodstream 
and their antigens are detected, the activation of the complement system can occur through 
three different pathways called the Classical pathway, the Alternative pathway and the Lectin 
pathway. Activation of these pathways leads to the serial activation of complement components 
where  activation of specific complement components results in opsonization of the bacteria 
with C3 fragments that bind to the bacterial surface and label it for more efficient phagocytosis. 
Activation of the complement system can also kill bacteria directly through the formation of a 
membrane attack complex (MAC). A variety of protein fragments are involved in the activation 
of the MAC and the destruction of the bacteria is through lytic effects25,26. In vitro, the 
complement pathway can be inhibited by either a physical (heat) or chemical (sodium 
polyanethole sulfonate, SPS) inactivation. SPS is currently used as an anti-coagulant and 
complement inhibitor in blood cultures in the clinical setting, and blocks the activation of the 
classical and alternative complement pathways, whereas the lectin pathway is not inhibited41. 
Not all bacteria are equally sensitive to direct complement killing, where some strains can be 
serum resistant and thus thrive in human blood. Depending on the surface of the bacteria, the 
susceptibility to serum can vary42,43. In addition to the complement system, other antimicrobial 
factors, such as lysozyme, can assist in the killing of bacteria in the blood20.  
E.coli is the most common cause of bloodstream infections, where strains with resistance to 
serum often express capsules or modified LPS, where a longer LPS structure is associated with 
serum resistance and initiation of complement-activation is located at a longer distance from 
the bacterial surface44. The blood also contains circulating monocytes and neutrophils that 
produce antimicrobial agents, including reactive oxygen species (ROS) and nitric oxide (NO) 
which exhibits potent effects on bacterial survival29.  A range of antimicrobial peptides and 
proteins can be found in the blood, mainly within circulating leukocytes and platelets and 
secreted in response to infection. Lysozyme and phospholipase A2 enhance the lysis of cells 
and work in combination with the complement system for efficient killing45,46. Additionally, 
LL-37 and bactericidal permeability increasing protein (BPI) neutralize endotoxins and cause 
direct killing of the pathogen47,48. When bacteria evade the bactericidal factors of the blood, 









2. GRAM-NEGATIVE BACTERIA  
Since the discovery of penicillin, methicillin resistance in Staphylococcus aureus and 
vancomycin resistant enterococci, Gram-positive bacteria were considered of most concern. 
More recently, Gram-negative infections have emerged as the most difficult to treat and cause 
clinical problems due to bacterial resistance49. Gram-negative bacteria allow for a silent and 
rapid exchange of genes, carrying resistance mechanisms to strains causing community onset 
and health-care associated infections50. 
 
2.1 THE OUTER MEMBRANE OF GRAM-NEGATIVE BACTERIA 
The outer membrane of Gram-negative bacteria is rich in lipopolysaccharides (LPS). LPS are 
large lipid molecules consisting of lipid A, an inner and outer saccharide core and a hydrophilic 
O-antigen. The lipid A acts as an anchor between the outer membrane and the sugar moieties 
of the LPS molecule and plays a role in stabilizing the bacterial outer membrane with its 
hydrophobic saturated fatty acyl chains49. Depending on the bacterial species, lipid A can 
present a different extent of acetylation and phosphorylation in different bacteria. In addition, 
the symmetry (depending on number of acyl chains) of the lipids can vary. The degree of 
phosphorylation of the lipid A can determine the net charge of the membrane (at specific areas 
or overall), giving a negative charge to the membrane49. The net charge is an important factor 
for the host immune response, including cationic AMPs that interact with the negatively 
charged areas, resulting in breakdown of the membrane49. The second part of the LPS is the 
inner core, which consists of sugars and is more highly conserved among bacterial species than 
the other two parts. The inner core is important for cell viability and has certain antigenic 
properties when the LPS does not contain any O-antigen51. The O-antigen consists of 
polysaccharides and stand out from the bacterial membrane into the extracellular environment. 
This glycan can vary in length and consists of repeating sugar units and can either be present 
or lacking in the LPS structure52. When the O-antigen is present, the LPS is referred to as 
smooth LPS (S)-form, while LPS lacking O-antigen is called rough LPS (R)-form. The O-
antigen plays an important role in pathogenicity and virulence of bacteria and is a highly 
immunogenic antigen and recognized by the host immune system. Rough LPS leaves the cell 
more permeable and thus more susceptible to antimicrobial agents and environmental factors, 
such as stress, which indicates that changes in LPS can have a great impact on the bacteria51. 
The outer membrane of Gram-negative bacteria is important for antimicrobial resistance 
properties, especially in bacteria such as K. pneumoniae that can also be coated with a thick 
polysaccharide capsule outside of the outer membrane and as a result is less affected by AMPs, 







Two of the most problematic Gram-negative bacteria with regard to antibiotic resistance belong 
to the family of Enterobacterales (formerly called Enterobacteriacae). They are non-spore 
forming, generally ferment glucose, reduce nitrate and can be either motile with flagellas or 
non-motile. The Enterobacterales are found in nature and constitute a part of our natural 
microbiota but can also become pathogenic and cause disease. In part, this depends on their 
ability to transfer and acquire specific virulence factors between strains. Numerous virulence 
factors can be transmitted between bacteria on mobile genetic elements; plasmids, which can 
result in highly pathogenic strains. The pathogenic strains have often acquired special adhesion 
or colonization attributes (pili), which help them to colonize places they usually do not reside 
in (e.g small intestines or urethra). These bacteria can also produces enterotoxins54. Similarly, 
transmission of genetic material between strains can lead to antibiotic resistant strains, where 
the overuse of antibiotics selects for these strains to survive and cause disease. Two members 
of the Enterobacterales family are E. coli and K. pneumoniae, which are common causes of 
bacterial infections, especially in the hospital setting1. Their ability to easily acquire resistance 
is of high concern today, with emergence of strains expressing extended-spectrum β-lactamases 
(ESBL) and carbapenemases55. Bacterial species, such as K. pneumoniae and E. coli have 
developed a protective mechanism by producing several iron-binding molecules, called 
siderophores (e.g enterobactin, salmochelin, yersiniabactin). Since iron is important for 
bacterial growth, siderophores constitute an excellent target for host immunity. Consequently, 
the host has developed ways to restrict access to iron by using LCN-2, which binds to 
siderophores and thus block iron-uptake by bacteria. It has been shown that LCN-2 is necessary 
for protection of the lung against K. pneumoniae and E. coli24,56. 
E. coli normally resides in the gastrointestinal tract and coexist with humans throughout the 
lifespan without any complications. Commensal E. coli is considered opportunistic and only 
cause infection when the gut barrier is breached or in immunocompromised individuals where 
the balance between the gut microbiota and the immune system is dysregulated. E. coli mainly 
cause gastrointestinal infections, urinary tract infections and sepsis/meningitis54.   
Similarly to E. coli, K. pneumoniae is carried by humans, mainly in the GI-tract, but can also 
be found in the upper respiratory tract and skin. The bacteria are rod shaped, non-motile and 
can have a variety of capsules that can be serotyped (K-typing) and are associated with 
virulence factors57. Infections caused by K. pneumoniae are mainly hospital acquired and 
presents as pneumonia, urinary tract infection or sepsis, mainly in the immunocompromised, 
neonates or the elderly58. However, hypervirulent strains can cause community acquired 
infections in previously healthy humans. These strains often belong to certain capsule 
serotypes, such as K1 and K259. In addition to K-typing, O-antigens are also used to type the 
bacteria, where O1 serotype is highly prevalent in clinical isolates. The capsule can protect 





3. ANTIBIOTIC RESISTANCE 
The first antibiotic was discovered by Alexander Fleming in 1928, isolated from the fungus 
Penicillium notatum60. Since then, a range of additional antibiotic-classes have been 
discovered, including cefalosporins, carbapenems, macrolides, and quinolones to mention the 
most important. However in recent years, with the arising problem of antibiotic resistance, 
inventing new classes of antibiotics has proven difficult and bacteria have rapidly gained 
resistance to the few novel antibiotic drugs that have been introduce to the market61.  
Antibiotics can be categorized in different ways according to their structure or mechanism of 
action. The classification by target includes antibiotics that interfere with the bacterial cell wall, 
the protein synthesis and DNA synthesis. β-lactams comprise the largest group of antibiotics 
and  have been shown to be very potent against bacteria for decades. All β-lactams have a 
conserved ring structure with various additional chemical groups for a variety of functions. The 
four membered β-lactam rings are responsible for the antibacterial effect by binding as a 
substrate to the Penicillin Binding Protein (PBP) on the bacterial wall, that cross link the 
peptidoglycan in the genesis of the cell wall, thus impairing cell wall synthesis for replicating 
cells resulting in lysis of the bacteria. The β-lactams have multiple sub-classes that include 
penicillins, cephalosporins, carbapenems and monobactams, where carbapenems are reserved 
for the most complicated Gram-negative infections. Multiple resistance mechanisms exist, such 
as active efflux, reduction of bacterial membrane and cell wall permeability, altering 
transpeptidases, and the enzymatic inactivation of β-lactam antibiotics by β-lactamases62. 
Today,  resistance mechanisms have been discovered in bacteria that can affect every type of 
available antibiotics, and a special concern is the β-lactamase producing Gram-negative 
bacteria. In particular, the resistance to carbapenems is problematic and widespread, by virtue 
of the expression of carbapenemases61. When a bacteria is resistant to multiple antibiotic types, 
the terminology MDR (Multi drug resistance) is used, while XDR and PDR refer to extensively 
drug-resistant and pandrug- resistant (pan referring to all antibiotics), respectively63. 
 
3.1.  HORIZONTAL GENE TRANSFER 
Bacteria have the ability to exchange genetic material (plasmids) through different 
mechanisms, which is crucial for their evolution64. The three main mechanisms for horizontal 
gene transfer are transformation, transduction and conjugation. Transformation is the process 
where foreign DNA from the environment is incorporated into the bacterial genome, often from 
either lysed cells or actively secreted material65. Transduction occurs through bacteriophages, 
where the phages replicate inside the bacterial cell and bacterial DNA can be incorporated in 
the phage capsids66. The third mechanism is conjugation, an important factor in antibiotic 
resistance. The genetic material is transferred from a host cell to a recipient cell through a 
passage or a secretion system, where the system is usually expressed by proteins on the 
plasmid67. Antibiotic resistance genes can be carried on plasmids and transferred between 
bacteria via horizontal gene transfer, most commonly through the third mechanism, plasmid 
 
 11 
conjugation. This results in a complicated fight against antimicrobial resistance, where one 
bacterium can spread a resistance mechanism easily to surrounding bacteria68,69.  
 
3.2. β-LACTAMASES 
The emergence of antibiotic resistance is not recent, but represent ancient events designed in 
nature that helped bacteria or fungal species to survive in a hostile environment full of 
competing species secreting antibiotic compounds. With the use of antibiotics, strains that did 
not contain any defenses against antibiotics were eliminated, while the bacteria that contained 
resistance mechanisms survived, and in that way were selected to survive and spread70. β-
lactamases are enzymes produced by bacteria that can cleave the four membered ring of β-
lactams, resulting in the inactivation of the antibiotic. This resistance mechanism is of special 
concern, where the gene expression of these enzymes can be transported between bacteria on 
plasmids, allowing for a fast spread. These enzymes have been classified by the Ambler system 
into different groups; A, B, C and D β-lactamases based on the molecular size and similarities 
in active sites of the enzymes71. Older classifications were made from the type of hydrolysis 
by the active site of the enzyme and how the enzymes cleave the antibiotics; serine-β-
lactamases and metallo-β-lactamases61. Classes A, C and D all belong to the group of serine-





















Figure 3. The activity of β-lactamases. β-lactam antibiotics bind to the penicilling-binding-protein (PBP) on the 
bacterial membrane, and impair the cell wall synthesis. β-lactamases are produced by the bacteria and cleave the 
beta-lactam ring of the antibiotics, which prevent them from binding to the PBPs. Figure reused with permission 
from the publishing journal72 
 
 
SERINE-β-LACTAMASES This group of β-lactamases have a serine amino acid in the active 
site of the enzyme that catalyzes the hydrolysis of the amide bond in the four membered β-
lactam ring, opening up the structure and preventing it to bind the PBP for inactivation of the 
cell wall synthesis. The importance of the serine residue is the interaction with the β-lactam, 
forming a covalent serine-bound acyl intermediate. The different groups of serine-β-lactamases 
show a conserved structure of the active site, suggesting a common origin in evolution, and are 
considered to go back 2 million years73. Various serine-β-lactamases have been identified and 
they are becoming more visible in health care, including extended spectrum β-lactamases 
(ESBL) that are known to break down cephalosporins, Klebsiella pneumoniae carbapenemase 
(KPC) and the oxacillinase (e.g OXA) that can hydrolyse carbapenems and penicillins 
respectively. The ESBLs have been shown to be inhibited by clavulanic acid, however the 
ESBL-producing bacteria pose a threat both in community and hospital settings, where 
outbreaks have been associated with ESBL carrying E. coli. A certain virulent variant of ESBL, 
the CTX-M family, has shown dominance within the ESBL-producing Gram-negative 
population. With the ESBL-producing isolates becoming more prominent in the hospitals, 
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antibiotics such as carbapenems, that had been reserved for more complicated infections, were 
increasingly used. This increased usage has resulted in isolates that have gained multiple β-
lactamases (MDR strains), where the combinations of β-lactam antibiotics and clavulanic 
acid/inhibitors is insufficient. This selection of strains with carbapenem resistance has made 
various available antibiotics inefficient against infections, and underlines the importance of 
finding alternative ways of resolving difficult infections73.  
 
METALLO-β-LACTAMASES The second type of β-lactamases are the metallo-β-
lactamases (MBL). The first MBLs identified were the enzymes IMP (Imipenemase-type 
metallo-β-lactamase) and VIM (Verona Integrated metallo-β-lactamase) that spread within 
Gram-negative pathogens including Enterobacteriales. More recently, the NDM (New Delhi 
metallo-β-lactamase) was identified in a patient in Sweden, arriving from India74. The different 
resistance genes are often associated with certain geographic areas, where they are thought to 
have originated, however the strains are spreading fast through the different parts of the world. 
As the name indicates, use of metals is essential for the function of MBL enzymes, where either 
one or two zinc ions are necessary to catalyze the hydrolysis of the β-lactam antibiotics. The 
hydrolysis does not result in a covalently bound intermediate. The enzyme catalysis begins 
with the binding of the β-lactam in the active site of the enzyme that contains the metals, where 
zinc stabilizes the hydroxide ion in the binding site, that with a nucleophilic attack reacts with 
the carbonyl carbon of the β-lactam, leading to the formation of a tetrahedral-intermediate that 
results in breaking of the amide bond of the β-lactam. The active sites of these enzymes are not 
as conserved as the serine-β-lactamases, but have more variety, which indicates that they did 
not have a common evolutionary origin. The MBLs belong to the Ambler B class of β-
lactamases and have constituted a real challenge and have shown to be difficult to inhibit in 
vivo62. 
 
3.3. β-LACTAMASE INHIBITORS To treat infections caused by resistant bacterial strains, 
different combinations of antibiotics have been used, and the use of broad spectrum antibiotics 
has given the strains the opportunity to accumulate different resistance mechanisms and 
become resistant to multiple antibacterial agents at once. In addition to combining different 
types of antibiotics, treatments of infections caused by antibiotic resistant pathogens have 
focused on combining β-lactamase inhibitors with antibiotics61. A number of serine-β-
lactamase inhibitors have been identified, including the above mentioned clavulanic acid, as 
well as sulbactam and tazobactam. Other novel inhibitors have been made available, such as 
avibactam, relebactam and vaborbactam, however none of these show activity agains 
MBLs75,76. The zinc dependency of the MBLs led to the finding that EDTA (divalent metal 
chelator) could be used as an inhibitor77. However EDTA is highly toxic and thus not a viable 
treatment option as an MBL inhibitor in humans. Nevertheless, EDTA is used in the laboratory 
to identify MBL-expressing isolates. While the synthesis of MBL inhibitors have not given 
much success in recent years, multiple studies have shown that chelating zinc can be a viable 
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option, and currently zinc chelating molecules and other possible inhibitors are being studied78. 
The natural compound aspergillomarasmine A has been shown to inhibit NDM-1 and VIM-2 
enzymes through inactivation by Zn2+ binding in the active site, and has shown efficiency in 
K. pneumoniae infected mice79. Certain compounds, such as thiol containing chemicals, can 
have zinc chelating abilities and have been proposed as inhibitors in combination with 
antibiotics80,81. The problem that may arise with these inhibitors is the toxic effect of the zinc 
chelation on the host. Research has thus focused on screening for compounds that do not bind 
the ions directly, but bind the active site of the metallo-β-lactamase82. The most promising 
inhibitors today are bicyclic boronates that have shown inhibition against both serine-β-
lactamases and metallo-β-lactamases83. 
Interestingly, eukaryotic cells have a regulated environment that is also depending on metals, 
such as zinc. Thus, it would be interesting to search for endogenous zinc chelators that possibly 
could be used to inhibit bacterial MBLs.  
 
4. BACTERIAL FITNESS 
Current research has revealed that the bacterial acquisition of antibiotic resistance mechanism 
comes at a certain cost of fitness for the bacteria84. Studies focusing on competition between 
susceptible and resistant bacteria have shown that the growth rate is slower when resistance 
mechanisms are present85–87. The current explanation for this is that increased energy is needed 
for the expression of different efflux pumps and enzymes, which can explain why the 
acquisition of resistance could alter the energy distribution of the bacterial cell, resulting in a 
cost of fitness85. Strains can also gain resistance against heavy metals (copper, silver, arsenic) 
in the environment, which might affect the survival in different circumstances88. In a study by 
Schrag et al, the presence of plasmids carrying resistance genes were associated with slower 
growth, which suggests that there is a cost of fitness for genetic alterations89, however this cost 
is strain-specific and the contribution of host defenses against resistant bacteria has been less 
studied.  
The cost of fitness has been efficiently studied on bacterial strains carrying chromosomally 
encoded resistance genes90–92. However plasmid borne resistance has recently been studied to 
a higher extent, where strains carrying antibiotic resistance encoded on plasmids come with a 
cost resulting in lower fitness87,90,93,94. Methodologically, the biological cost has mostly been 
studied with competition assays, where strains with selection markers are co-cultured, and the 
survival recorded. Other studies that include in vivo models have recorded similar results, 
mainly in murine models84. The research on biological cost of fitness for resistance acquisition 
in relation to host recognition and innate immune responses is very limited. 
It was concluded from research on strains transfected with an ESBL plasmid versus non-ESBL 
that no effect was observed on fitness in serum, however the focus of physical attributes of the 
bacteria was not taken into account95. Other studies on K. pneumoniae and E. coli from urinary 
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tract infections reported either no effect or beneficial effect of plasmid acquisition, indicating 
discrepancies and unclear data on serum sensitivity of ESBL and non-ESBL pathogens96,97. 
An important observation concerning the research on cost of fitness is that conditions used to 
assess growth are often similar to standards developed to test for antibiotic resistance, where 
bacteria are grown in optimal conditions. These standards are necessary to get comparable 
results around different laboratories, however it fails to take into account the physiological 
environment of infection, including innate immune factors. Different studies have addressed 
this issue, where the culture broth was adjusted by using a more physiological cell culture 
media (RPMI) supplemented with Luria broth (LB), which proved to have a major impact on 
experimental outcomes98. With new perspectives on host-pathogen interactions, by including 
the physiological environment of infection, research on bacteria and antibiotic resistance, and 
antibiotic resistance testing can most likely be improved99.  
An interesting research approach is to spread the focus from direct bactericidal effects to a 
broader perspective by addressing the problem from multiple directions. Using a monotherapy 
drug has been shown to result in a rapid acquisition of resistance mechanisms. While it is 
important to continue the search for more antibacterial drugs, another possible alternative 
would be to study and utilize pre-existing innate host defenses100.  
 
5. BLOODSTREAM INFECTIONS AND SEPSIS  WTIH FOCUS ON 
ANTIBIOTIC RESISTANCE 
When bacteria enter the bloodstream of patients, referred to as bacteremia, the immune system 
may react in a dysregulated manner, resultng in sepsis. According to the “Sepsis Definitions 
Task Force“, the term Sepsis-3 is defined as a101; 
“life-threatning organ dysfunction caused by a dysregulated host response to infection“ and 
“Septic shock is a subset of sepsis in which underlying circulatory and cellular/metabolic 
abnormalities are profound enough to substantially increase mortality“101. 
To cause an infection, bacteria can cross the mucosal barrier and invade different organs, such 
as the urinary tract, lungs, skin and soft tissues, which is followed by fever, chills and/or 
hypertension. E. coli and K. pneumoniae are two common causes of bacteremia and sepsis102. 
The dramatic increase in antibiotic resistance in those species, makes them highly dangerous 
infectious agents in a clinical setting, where rapid discovery and treatment is important to avoid 
morbidity and mortality. The spread of antibiotic resistance varies in different parts of the 
world, for example, a study by Quan et al, showed that E. coli isolated from bloodstream 
infections exhibited an ESBL-phenotype in 55% of the cases in certain parts of Asia103. In the 
EU the prelevance of ESBL β-lactam resistance in E. coli was 14.9% in 2017. Notably, the 
prevalence of carbapenem resistance in K. pneumoniae  was over 10%, while carbapenem 




6. HOST DIRECTED THERAPY 
With fewer available antibiotic treatments, due to increased antibiotic resistance of bacteria, 
novel and alternative methods need to be explored to resolve bacterial infections. The innate 
immune system consists of various ancient effectors that attack invading pathogens, and 
research on the innate immune effector systems has revealed that they can be manipulated and 
induced by external stimulation using simple drug-like compounds14,17,18,31,100,105. While 
monotherapy, with either antibacterial drugs or innate antimicrobial effectors pose the risk of 
resistance106, inducing multiple immune responses through different mechanisms could be a 
key strategy in the search for alternative methods100. 
Some bacteria have developed mechanisms to alter or suppress the immune responses of the 
host for its own advantages to establish an active infection. Both epithelial cells and innate 
immune cells have a basal expression of AMPs to prevent bacteria from entering through the 
barrier and establish an infection. Studies have shown that Shigella species have the ability to 
downregulate the expression of human cathelicidin (LL-37) and human beta defensin 1 (hBD-
1) through plasmid DNA to evade the immune survival at the first line of defense107, while 
other studies reported that secreted proteins from the Shigella bacteria mediated the 
downregulatory effect 108. As a proof of concept, Shigella was found to downregulate CAP-18 
(the cathelicidin ortologue in rabbits) in the large intestines in a rabbit model109. More studies 
have demonstrated a downregulation of cathelicidin by Vibrio cholerae and E. coli in the large 
intestines through cholera and labile toxins, respectively110. In addition, it has been found that 
Neisseria gonorrhoeae downregulate LL-37 in a human cervical epithelial cell line111. 
Currently known inducers of AMPs in humans include vitamin D3, which is a potent inducer 
of the CAMP (cathelicidin antimicrobial peptide) gene expression13. This induction has been 
studied in vitro and in vivo, where it is specific through gene responsive elements in the vitamin 
D3 receptor (VDR) in primates, an element inserted late in evolution. For this reason, rodent 
cathelicidin genes do not respond to vitamin D3 and rodents have therefore not been candidates 
for in vivo experiments studying vitamin D3 -mediated effects on cathelicidin-expression
112,113. 
In the gut, the microbiota, the epithelial cells and immune cells exist in a homeostatic system, 
which in the healthy state prevent pathogenic bacteria to invade the body and promote the 
normal flora to thrive. This homeostatic system involves the release of metabolic products such 
as butyrate (a short chain fatty acid) from the normal flora, which results in the production and 
secretion of AMPs. Butyrate is a known inducer of LL-37 and has been studied along with 
phenylbutyrate (PBA) as potential drugs for host directed therapy114. Butyrate and PBA are 









Figure 4. Host-directed therapy. A) The normal gut microbiota is dependent on expression of AMP‘s. Mucins are 
indicated by the grey zone at the apical site of the cells and AMPs by symbols. B) Some pathogens (red) can 
downregulate the expression of AMPs and disrupt the epithelial barriers. C) Downregulation can be counteracted 
by inducers. D) The pathogens are eliminated when AMP expression is restored. Figure reused with permission 
from the publishing journal100. 
 
The two inducers, vitamin D3 and PBA, have been studied in combination, where both in vitro 
and in vivo studies have revealed a synergistic induction of CAMP gene expression in the 
presence of both vitamin D3 and PBA
15,116,117. Another potent inducer was found through 
screening of a chemical library to search for the induction of AMPs and the HDACi Entinostat, 
an approved drug used in combination with chemotherapy of cancer, was identified. Entinostat 
was effective in a rabbit-model for Shigella spp and Vibrio Cholera infections. However, the 
drug was found to be slightly toxic at higher concentrations118,119. Therefore, the search for 
additional AMP-inducers have continued and our research-group has identified a novel class 
of inducers (aroylated phenylene diamines), where the compound HO-53 was selected for 
further studies120. 
Pathogens such as Mycobacterium tuberculosis (Mtb), Salmonella and Legionella have 
evolved and acquired the ability to circumvent or block autophagy inside cells121. Autophagy 
is an important cellular defense mechanism to eliminate phagocytosed pathogens, and serves 
as an interesting target mechanism for host directed therapy38. Vitamin D3 has been shown to 
activate autophagy as well as inducing the autophagy genes (ATG-5 and Beclin-1). The 
combination of vitamin D3 and PBA showed a further increase in autophagy activation
122,123.  
The activation of autophagy is a delicate balance, where the beneficial effect appears to be 
pathogen specific. Mtb have the mechanism to specifically downregulate autophagy by 
blocking the fusion of the phagosome and lysosome within the cell. With this, the bacteria can 
survive intracellularly in human macrophages, which contributes to their virulence124,125 
Activating the autophagy has been linked to increased killing of Mtb126. In contrast, 
Staphylococcus aureus and Pseudomonas aeruginosa on the other hand can use autophagy to 




Another important mechanism for bacterial killing and clearance is the ROS production. ROS 
is used both during phagocytosis, is released as a response to pathogens, and has to be closely 
regulated to avoid self damage to the cells29. The induction of ROS-production in a controlled 
and local manner could be an interesting approach aas a part of host-directed therapy against 
bacterial infections. 
A link between ROS and antibiotic susceptibility has been proposed, where the increase in 
ROS upon antibiotic treatment has been recorded after ciprofloxacin treatment, as well as the 
killing efficacy of antibiotics, such as aminoglycosides, fluoroquinolones and β-lactam 
anticiotics was shown to be decreased under anaerobic conditions. The link between ROS and 
the effects of antibiotics has been contradictory due to difficulties in measuring ROS.130. 
The concept of host-directed therapy as a way to fight MDR bacteria is a promising research 






2 AIM OF THE THESIS 
 
The general aim of the thesis is to gather knowledge on the connection between the innate 
immune system and multidrug resistant bacteria, to study host-pathogen interactions and 
examine the effects of host innate effectors on resistance mechanisms in Gram-negative 
bacteria. 
 
• To study the impact of cellular supernatants on the effects of antibiotics against 
multidrug resistant K. pneumoniae (Paper I) 
 
• To  evaluate the effect of novel inducers of innate immune effectors (AMPs, ROS and 
autophagy) in human macrophages to eliminate multidrug resistant K. pneumoniae. 
(Paper II) 
 
• To evaluate the survival of ESBL and non-ESBL E. coli isolates against innate 
immune effectors in vitro and in vivo (Paper III)
 
 21 
3 METHODOLOGICAL CONSIDERATIONS 
 
Here I will review some methodological aspects in relation to my studies. I will focus on the 
isolates selected for the studies and the main methods used, including bacterial survival, cell 
culture and infections in vitro and in vivo as well as plasmid transfer.  
In Study I-III, clinical isolates were used (E. coli and K. pneumoniae), isolated from 
bloodstream infections, retrieved from blood cultures and analyzed at the Karolinska 
University Laboratory in Stockholm (2013-2014). The isolates were characterized for 
antibiotic susceptibility and β-lactamase expression. In study III, a collection of randomly 
selected ESBL and non-ESBL E. coli isolates was used. 
Bacterial survival was evaluated with two methods in Study I-III, with a colony forming unit 
assay (CFU assay) and with Bioscreen C survival curve generator. For both methods, a colony 
from a blood agar plate was cultured in the desired broth (LB or MHB broth) at 37°C and 
allowed to reach exponential phase. The bacterial suspension was then diluted to a working 
concentration (Optical density, OD600) with appropriate conditions for each experiment in 
either a 96 well round bottom plate (CFU assay) or a Honeycomb plate (Bioscreen). 
Whole blood/serum killing of bacteria was performed with a CFU assay in Study III. Blood 
was collected from healthy volunteers in either a heparin tube (whole blood) or coagulation 
tube (serum). The whole blood and serum were diluted in broth to a final concentration, and 
bacteria suspension added to the well. A CFU assay was then performed and survival was 










Figure 5. CFU counting. When bacteria had been treated with the selected treatment (drugs, blood components, 
inducers), the suspension was diluted tenfold to produce 8 dilutions including the initial suspension. Each dilution 
was plated on a blood agar plate divided into 8 parts to visualize the logarithmic differences in bacterial survival. 





Statistical analysis of viable CFU counting can be complex due to the extreme range of 
CFU/ml between conditions and experiments. To account for this, the CFU/ml were log 
transformed (where 0 CFU counts were considered as 1 CFU to allow for the logarithmic 
transformation). This transformation was followed by an ANOVA or t-tests for normally 
distributed conditions, or Mann-Whitney and Kruskal-Wallis in the case of ranked test.  
To study the effect of AMP inducers in Study II, primary cells (peripheral blood mononuclear 
cells) were isolated from buffy coats and cultured into macrophage like cells in the presence of 
human macrophage colony stimulating factor (M-CSF), directing the differentiation towards 
an M1 state (pro-inflammatory) (phenotype confirmed via flow cytometry by a collaborating 
group)131. The cells were chosen for their phagocytosis and differentiation potentials. While 
human monocyte cell lines are available (THP-1 cells), the primary macrophages were 
considered more relevant for the purpose of AMP induction. The cells were analyzed through 
bacterial infections, Real-time PCR (RT-PCR) and Western blot analysis. 
The primary macrophages were used as a model for a gentamicin protection assay in Study 
II, where the cells were stimulated with the treatment and infected with either a WT or MDR 
K. pneumoniae. The isolates used for the infection were susceptible to the antibiotic 
gentamicin, which is known to have no or limited intracellular activity. Gentamicin was added 
to the macrophages to kill extracellular bacteria, allowing for evaluation of live intracellular 
bacteria through lysing of the cells, plating and counting viable colonies. In study II, the use 
of vitamin D3 as an inducer required the macrophages to be from humans (AMP induction and 
responses alter between species), however in study III the need for a human cell line was not 
present and the mouse macrophage cell line RAW 264.7 was cultured and used in the 
gentamicin protection assay. Using a cell line eliminates the need for live donors and can 
provide rapid and reliable results without donor variation. 
In study I, supernatants were collected from HT-29 cells, a cell line established from human 
colon cancer cells120. The cells were selected for the relevance to intestinal infections and were 
only used to produce supernatants, eliminating the need to establish a primary cell model. The 
supernatants were further used in the search for an endogenous β-lactamase inhibitor. 
In study III, a Zebrafish embryo infection model was utilized for in vivo experiments. The 
zebrafish have emerged as an exceptional tool to study the immune system. The optical 
transparency of the fish, the accessibility to visualize the organs and the rapid development 
from embryo to fish gives this model a great advantage. The jump from in vitro cell culture to 
in vivo mouse studies is very high, and the zebrafish model reduces this jump in both time, cost 
and accessibility.  
The generation of genetically altered lineages is highly successful in the zebrafish, where gene 
inactivation and transient gene knockdown has proven a useful tool to gain information into 
genetics and cell biology. The model has been used extensively to research hematopoietic and 
lymphoid development, where gene expression data from microarrays can be used to study 
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differences in gene expression between wild type and mutant embryos. This research is crucial 
in the understanding of genetic conditions and genetic diseases in humans132.  
The zebrafish is an efficient tool for drug discovery, having the advantage of phenotype-based 
screening, where more variables such as pain, sedation, tumor metastasis, vascular tone and 
gut motility of a disease can be recorded. The model also provides a very early insight into a 
drug’s toxicity on different organs, which is limited in cell-based assays. The relevance of an 
animal model to human physiology is an important factor to consider. There are always 
limitations on each animal model used, however recent studies have shown that 82% of disease-
associated targets in the zebrafish are shared with humans, where the zebrafish physiology is 
highly conserved133. 
The focus of this thesis is based on the innate immune system. The zebrafish have been found 
to exhibit innate immune defenses the resemble the human innate immune system. They have 
circulating erythrocytes, neutrophils, eosinophils, lymphocytes, macrophages, dendritic cells, 
exhibiting a highly conserved hematopoietic system134.  
The zebrafish express TLR’s on the surfaces of macrophages and dendritic cells and recognize 
conserved pathogenic traits through PAMP’s132. The complement system of the zebrafish has 
been studied extensively, showing all the homologs of the mammalian complement 
components being present. This suggests that the complement system in the zebrafish is similar 
to the mammalian/human complement system, both structurally and functionally135. Finally, 
antimicrobial peptides have been discovered in the zebrafish136, emphasizing the relevance 
of this animal model to the research on innate immune defenses and host directed therapy. 
In study III, the method of zebrafish microinjections was utilized, where bacteria were injected 
into the embryos and the survival of the embryo/fish recorded over 5 days. This method does 
not allow for pre-treatment of the fish since the embryo can only be injected once due to the 
embryos fragility, however the method shows great promise when studying different bacteria 
in the fish, or the effect of genetic modulation to the innate immune defenses. 
In study I and study III, a bacterial trans-conjugation method was used to transfer plasmids 
from one bacterial strain to another. Plasmid trans-conjugation requires a defined selection for 
each strain, which can be difficult to achieve with clinical isolates. For this method, a two-step 
trans-conjugation was performed, moving the resistance plasmid from the clinical isolate into 
an intermediate strain with a double selection. This method constitutes of a donor strain 
containing VIM-1 (Study I) or ESBL (Study III), an intermediate strain, and a final recipient 
strain. Importantly, the donor strain is required to be susceptible to chloramphenicol, and 
resistant to the selection antibiotic (AB) (e.g ampicillin). The intermediate strain was 
susceptible to the selection antibiotic, resistant to chloramphenicol, and dependent on 2,6-
diaminopimelic acid (DAP)(Δdap). For the first step of the plasmid transfer, using a selection 
antibiotic, DAP and chloramphenicol selects only for the intermediate strain that has acquired 
the plasmid (with a DAP (-) control showing no growth). For the second step of the transfer, a 
final recipient strain, susceptible to the selection antibiotic was trans-conjugated with the 
intermediate strain, selecting the final product with the selection antibiotic only without DAP, 
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allowing the growth of the final recipient that has acquired the plasmid only (no DAP, with 
selection antibiotic) (Figure 6) 
 
 
Figure 6. Plasmid transconjugation selection. Strains with different selection markers were used to form the final 
product of a final recipient strain containing an ESBL/VIM-1 plasmid. The donor strain (clinical isolate) 
conjugated with an intermediate strain (resistant to CHL, DAP dependent and AB susceptible), resulting in a the 
intermediate strain containing the plasmid (selection AB killing intermediate without plasmid, chloramphenicol 
killing the original donor). In the second step, the intermediate+plasmid strain (CHL resistant, AB resistant, DAP 
dependent) is conjugated with a final product (AB susceptible) and selected with AB only (no DAP), allowing for 
the growth of the final recipient that has acquired the resistance plasmid. Selections were performed with single 
selection controls. 
 
To avoid the occurrence of false positive growth, all steps of the trans-conjugation included a 
single or zero selection controls. If the intermediate strain with the plasmid grew in the absence 
of DAP, a false positive selection had occurred. This was followed closely, and the plasmid 
acquisition was confirmed with a colony PCR using primers for the transferred plasmid on all 
strains involved in the selection (donor strain, intermediate strain, intermediate strain with the 
plasmid, the final recipient strain and the final recipient strain with the plasmid). 
To conclude, the main methods used in Study I-III have been described in detail, including 












4 RESULTS AND DISCUSSION 
(for more detailed information, see papers I-III)  
THE IMPORTANCE OF THE MICRO- ENVIRONMENT FOR THE EFFECTS OF 
ANTIBIOTICS DURING INFECTION 
Study I was concluded in the published paper “Klebsiella pneumoniae expressing VIM-1 
metallo-β-lactamase (MBL) is re-sensitized to cefotaxime via thiol-mediated zinc chelation”. 
The study was focused on searching for cellular factors with the capacity to inhibit 
carbapenemases. Antibiotic resistance in bacteria is normally measured in a standardized 
nutritious experimental environment, which is important to maintain consistency and accuracy 
between different laboratories137. The general conditions under which antibiotic resistance is 
evaluated is however not representative of the local host environment where the infection is 
established98.  
In this study, K. pneumoniae isolates expressing different β-lactamases were screened for 
susceptibility against cefotaxime when cultured in the presence of cell culture supernatants 
from colon epithelial cells. The cells produce and metabolize various components that can 
influence bacterial survival and antibiotic susceptibility. Two of the isolates tested (both 
expressing VIM-1 metallo-β-lactamases) showed increased susceptibility to cefotaxime, while 
clinical isolates expressing NDM, KPC and OXA did not. Different antibiotics were tested 
together with the supernatant, however a restored susceptibility was detected only for 
cefotaxime and ceftriaxone (third-generation cephalosporins). Given that the VIM-1 enzyme 
is a zinc dependent metallo-β-lactamase, the role of metal chelation was studied by exchanging 
the supernatant for RPMI cell culture media supplemented with EDTA. By using EDTA 
treatment, as well as metal supplementation in the supernatant, it was concluded that zinc 
chelation was an important factor for the observed resensitization effect.  
To study if the supernatant contained a zinc chelation component, or if the cause for this effect 
was the lack of available zinc, the supernatant was subjected to various filtration- and chemical 
treatments. The active component was identified as a small (<3kDa), hydrophilic compound.  
Finally, with the use of L-cystine and L-cysteine, and substituting the cell culture media  to 
DMEM without L-cystine, it was concluded that the cells convert L-cystine (from 
RPMI/DMEM media) to L-cysteine (generating free thiols) that chelate available zinc, and thus 
prevent the VIM-1 enzyme from hydrolyzing the antibiotics. This was confirmed further by 
the addition of glutathione (both oxidized and reduced form), and the use of L-cystine that 
emits a fluorescent signal when reduced to L-cysteine. Blocking the thioredoxin pathway 
resulted in a dose dependent decrease in the conversion of L-cystine to L-cysteine. 
To study if the genetic background of the bacteria was responsible for the observed 
resensitization, a two-step plasmid transconjugation was performed on the VIM-1 producing 
strain (AO15200). The plasmid was transferred to two neutral backgrounds (E. coli ATCC 
25922 and MG1655). The E. coli strains carrying the VIM-1 plasmid exhibited the same re-
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sensitization to cefotaxime in the presence of L-cysteine, confirming that the zinc chelation 
ability of thiols inhibited the activity of the enzyme. 
Gram-negative bacteria are a common cause of urinary tract infections that can lead to 
bacteremia and sepsis138,139. Urine is a thiol rich fluid and the growth of the bacteria was studied 
in urine samples from healthy volunteers140. When the supernatant was replaced with diluted 
urine, the VIM-1 producing bacteria was susceptible to cefotaxime. When the urine was 
fractionated, the effect was observed in the same fractions where L-cysteine was found, 
confirming that the thiols in urine were a contributing factor to the re-sensitization to 
cefotaxime. Re-introducing zinc into the system regained the resistance and growth of the 
bacteria.  
MBLs require zinc to hydrolyze β-lactam antibiotics. Given the data from Study I on VIM 
producing strains the same should apply to other MBLs. The three common MBLs include 
VIM, IMP and NDM, where IMP expressing strains were not accessible for this study, but 
NDM strains were screened. However, NDM-producing clinical isolates are known to carry 
other resistance plasmids (such as ESBL), which would counteract the effect observed in the 
supernatant. When a lab strain expressing only NDM resistance was acquired, a similar 











INDUCING THE INNATE IMMUNE SYSTEM TO ELIMINATE MDR BACTERIA 
In Study II, we hypothesized that induction of innate immune effectors in human macrophages 
would contribute to intracellular killing of MDR bacteria. To that end, primary macrophages, 
differentiated to an M1 pro-inflammatory phenotype141, were treated with known inducers of 
AMPs for 24 h before the addition of both MDR and antibiotic susceptible K. pneumoniae. All 
inducers: PBA, vitamin D3, PBA + vitamin D3, HO53 and HO53 + vitamin D3, reduced the 
intracellular survival of both K. pneumoniae strains.  Notably, the inducers did not have a direct 
killing effect on the bacteria. 
Antibiotics that were found ineffective against the MDR K. pneumoniae were added to the cells 
during the infection to study the potential of further enhancing the killing of the bacteria. The 
antibacterial effect of azithromycin, cefotaxime, ciprofloxacin and fosfomycin was found to be 
enhanced with different combinations of inducers. Azithromycin activity was enhanced when 
the cells had been treated with PBA, vitamin D3 + PBA, HO53 and HO53 + vitamin D3. 
Similarly, cefotaxime activity was enhanced with PBA + vitamin D3, HO53 and HO53 + 
vitamin D3. Ciprofloxacin activity was enhanced together with PBA, + vitamin D3, HO53 and 
HO53 + vitamin D3, while fosfomycin had less potent killing enhancement with the inducers, 
showing a difference only with the combination of PBA + vitamin D3 and HO53 + vitamin D3. 
This suggests that pretreatment of human macrophages with inducers of innate effectors has 
the potential to sensitize the cells to allow for enhanced killing of MDR bacteria. In addition, 
some conventional antibiotics have been shown to directly activate innate effector mechanisms 
in host-cells100. This phenomenon likely contributed to the enhanced intracellular killing 
observed in this project. Host directed therapy exploits alternative and more diverse ways to 
eliminate pathogens, whereas monotherapy with conventional antibiotics may be ineffective or 
lead to rapid development of resistance. 
To dissect which effector systems were involved in the enhanced bacterial killing, 
transcriptional changes of a number of key genes were analyzed.  Notably, the expression of 
the CAMP-gene, encoding LL-37 and HBD-1 was induced by PBA, vitamin D3 and HO53. 
The inducers activated other AMPs, such as HBD-2 and HBD-4, and the oxidative stress genes 
nitric oxide synthase-2 (NOS2), dual oxidase 2 (duox2), the catalase encoding gene CAT and 
glutathione peroxidase 3 (GPx-3). Finally, the inducers activated autophagy related genes (atg5 
and atg12), indicating a diverse innate immune response by the inducers including 
antimicrobial peptides, reactive oxygen/nitric species and autophagy. 
The inducers were originally selected based on the induction of the CAMP gene encoding LL-
37, however more diverse effects on innate immune effectors were observed. To study to which 
degree LL-37 was involved as a contributing factor in the outcome of the bacterial killing, LL-
37 was silenced in the macrophages with siRNA. Bacterial growth was restored when LL-37 
was silenced, despite the presence of the inducers, PBA and/or vitamin D3, emphasizing the 
importance of LL-37 for bacterial killing. HO53, an HDACi, did not show the same effect on 
bacterial growth, suggesting a different mechanism of action for this compound within 
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macrophages (Figure 5). Next, we used macrophages deficient in reactive oxygen species 
production from a patient with a genetic mutation in the CYBB gene, and healthy macrophages 
where the CYBB-gene was silenced. Interestingly, an impaired intracellular killing capacity 
with PBA, vitamin D3, PBA + vitamin D3, HO53 and HO53 + vitamin D3 was observed in 
these cells, indicating that macrophages indeed require ROS production to inhibit bacterial 
growth (Figure 6). Finally, the importance of autophagy was confirmed using an autophagy 
inhibitor, resulting in the same trend of increased bacterial growth and abolished effect of the 
inducers (Figure 7). The results from Study II underline the potential to induce innate immune 
responses, alone or in combination with conventional antibiotics, to combat infections caused 
by MDR K. pneumoniae. 




ESBL-PRODUCING E. COLI ARE MORE SUSCEPTIBLE TO INNATE 
EFFECTORS THAN NON-ESBL E. COLI 
 
In Study III we hypothesized that ESBL-producing E. coli would be more susceptible to innate 
immune effectors than non-ESBL E. coli. The rationale was based on the fact that 
immunosuppression is a risk-factor for invasive infections with MDR bacteria in general. 
However, the underlying mechanisms are poorly understood. To test this hypothesis, E. coli 
isolated from bloodstream infections were analyzed in the presence of innate immune defenses. 
The isolates were randomly selected from a larger collection and categorized into ESBL-
producing isolates or non-ESBL isolates, and the susceptibility to innate immune defenses were 
studied (serum, whole blood, AMPs, intracellular killing in macrophages). A total of 60 isolates 
(out of n=142) fit the criteria; E. coli ESBL producing (n=30) or non-ESBL isolates (n=30). 
First, the isolates were tested for survival in human serum and ESBL producing isolates 
survived to a significantly lower degree compared to non-ESBL isolates.  
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From the collection of 60 E. coli isolates, 10 isolates were randomly selected from both groups, 
resulting in a selection of 21 isolates (10 ESBL, 10 non-ESBL and 1 ATCC reference strain), 
which were chosen for further analysis. Again, the ESBL isolates exhibited significantly lower 
survival in human whole blood and serum, and heat inactivation of the serum abrogated the 
killing. This suggests that the complement system is an important contributor to the difference 
of survival between ESBL and non-ESBL producing isolates in serum. The intracellular 
elimination of the pathogens was also studied with RAW 264.7 macrophages, where ESBL 
producing isolates had lower intracellular survival compared to non-ESBL isolates. 
The cost of fitness associated with antibiotic resistance has been studied mostly in the form of 
internal fitness of bacteria, such as growth rate85. The results from Study III however suggest 
that there is a biological cost connected to the ESBL phenotype in the form of increased 
susceptibility against innate immune responses. The reason for this cost could be related to the 
presence of the ESBL plasmid itself, or connected to the genetic background (chromosomal 
genes) of the bacteria. Both alternatives were explored by 1) transferring the ESBL plasmid 
from a clinical isolate to a clean background via plasmid trans-conjugation, and 2) analyzing 
the genomes of the different isolates and comparing non-ESBL isolates to ESBL isolates.  
A trans-conjugation setup was utilized, moving the ESBL plasmid from a clinical isolate, 
through an intermediate selection strain, and finally into an ATCC 25922 lab strain. The results 
showed no significant difference between the ATCC 25922 strain and the ATCC-ESBL 
conjugate in either serum or whole blood, suggesting the plasmid transfer did not alter the 
survival of the bacteria. The 21 isolates were sequenced and genomic data was compared with 
regard to: serotype, sequence type, antibiotic resistance and virulence factors. With a small 
cohort of 21 subjects, correlation studies were difficult to perform, however a difference was 
observed in the serotype distribution of the E. coli isolates where the two groups showed a 
distinct separation in O and H antigens.  
The increased susceptibility to serum was further studied in an in vivo zebrafish embryo model. 
Embryos injected with RS020 (non-ESBL) had lower survival compared to RS006 (ESBL), 
which confirmed the results that the ESBL isolates were eliminated more efficiently than non-
ESBL isolates in vivo. Additionally, the transconjugants were studied in the zebrafish model, 
and no significant difference in survival of the embryos injected with the ATCC 25922 strain 
and ATCC-ESBL transconjugant was observed. 
The data from Study III suggests that increased serum susceptibility of ESBL producing 
isolates is dependent on the genetic background and potential structural differences in the 
bacteria, and not the ESBL plasmid acquisition per se. The study was limited to a small number 
of clinical isolates and expanding the sequencing and genetic analysis to a larger collection 




Figure 9. A graphical summary of Study III. The main results from Study III have been compiled in a graphical 
summary 
 
Together, Study I-III highlight the importance of the tissue micro-environment and innate 
immune defenses for the pathophysiology and treatment of multidrug resistant bacteria. 
Studying the host-pathogen interactions and environment could be the key to solving the 
increasingly difficult problem of antibiotic resistance, where according to Study I, the 
contribution of the host is an important consideration. Study II addressed the possibility of 
using inducers of innate immune defenses (AMPs, ROS, autophagy etc), which could be a 
promising alternative or addition to current treatment options. Finally, Study III presents the 
differences between ESBL producing and non-ESBL E. coli in the presence of blood and its 
components underlying the contribution of the host response to invading pathogens.  
Finding ways to regulate the environment at the site of infection and the availability of 







5 FUTURE PERSPECTIVES 
Past research on antibiotic resistant bacteria has mainly been focused on the direct inhibition 
of the resistance mechanisms, as well as finding new antibacterial compounds. The search for 
inhibitors of MBLs has been ongoing for years, however no clinically available inhibitors are 
currently accessible. A novel compound, ANT431, has been developed as an MBL inhibitor142. 
The inhibitor was active against purified NDM-1 and VIM-2 enzymes and in combination with 
meropenem on NDM-1 Enterobacterales, however, the activity had limited range against 
different MBLs. The limited range of MBLs inhibited by this compound will most likely 
prevent the inhibitor to become a clinical candidate, but can be used as a model for further 
research143. Multiple inhibitors for serine-β-lactamases have been discovered, and research is 
still ongoing in developing new compounds. A new inhibitor VRNX-5133 has been developed, 
showing activity against both serine-β-lactamases, as well as VIM and NDM in P. 
aeruginosa144. The development of novel β-lactamase inhibitors is constantly ongoing, 
however the use of monotherapies might become outdated, since resistance to both β-lactams 
and β-lactamase inhibitors is emerging rapidly143.  
Targeting the host-pathogen interaction could be an alternative option to combat antibiotic 
resistant bacteria. Accessing the problem from diverse directions, along with the discovery of 
novel antimicrobials and inhibitors, is a promising alternative for future research and 
treatment100. More diverse ways to target the host-pathogen interactions have been proposed, 
such as the neutralization of virulence factors, blocking epithelial adherence and biofilm 
formation, the use of monoclonal antibodies against key pathogens, toxin neutralization and 
more specific methods to alter this interaction during infection, that focus on suppressing the 
growth and survival of the bacteria, leaving them harmless instead of directly killing the 
pathogen145. For this to become an alternative, methods of antibiotic susceptibility need to 
evolve in the direction where the host environment is taken into account, determining minimum 
inhibitory concentrations in assays that are relevant for in vivo infections99. 
The use of omics and computer simulations is becoming increasingly accessible and useful in 
many fields of biology. Sequencing technologies are more cost efficient and the generation of 
whole genome sequencing data has become a standard technique. The gradual development in 
omics (such as transcriptomics, metabolomics and proteomics) allows for a broader use of 
datasets, combining different methods to determine structure, function and potential 
antimicrobial activity of compounds. The interaction between pathogens and antimicrobials is 
complex and can include many different targets and pathways. Computational models will 
likely become a leading technological method in the host-pathogen interactions and the 




6 CONCLUDING REMARKS 
The studies compiled in this thesis have together highlighted the importance of considering 
the host cellular environment, metabolism and immune responses in the fight against MDR 
infections. Host-cells regulate both the extracellular and intracellular environment through 
metabolism and maintain a controlled tissue micro-environment. The availability of 
nutrients, metabolites and essential metals can limit (or sustain) the bacterial survival and 
potential of infection. Targeting the antibiotic resistance mechanisms directly by limiting 
the availability of extracellular components needed by the bacterium (Study I) or inducing 
the cellular response to infection could be key factors in managing the infection (Study 
II). It is vital to gain more information if the host response can possibly distinguish 
between non-resistant and resistant pathogens. Given the results that MDR strains may be 
more sensitive to innate immune defenses (Study III), the development of host directed 
therapy emerges as a strong and promising alternative or addition to mono-therapeutic 
methods. The fields of pharmacology, immunology and microbiology have remained 
separate, while research areas in oncology, for example, have evolved together with 
immunology. This has resulted in a breakthrough in cancer therapeutics and sets an 












Figure 10. Study I-III compiled in a schematic picture. Study I explored the role of tissue environment in 
the process of antibiotic resistance. In Study II, inducers of innate immune effectors were used to reduce 
intracellular bacteria survival within macrophages. Study III showed that the innate immune system affects 
non-resistant and resistant bacteria differentially, all together emphasizing the importance of developing 
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